Objectives: To report the successful use of rituximab on salivary gland immunohistology and function in a patient with Sjögren’s syndrome (SS) and associated MALT lymphoma.
Case report: The patient was a 42 year old woman with primary SS and associated MALT lymphoma located in the parotid gland and the hard palate. Four infusions of rituximab (375 mg/m2) weekly resulted in complete remission of the lymphoma. An incision biopsy of the parotid gland before and after treatment showed improvement of the (immuno)histopathological characteristics of SS, with possible regeneration of salivary gland tissue. Furthermore, salivary analysis showed decreased inflammatory characteristics and increased stimulated salivary flow.
Discussion: Rituximab is a promising agent in the treatment of SS associated MALT lymphoma. In addition to the effect on MALT lymphoma, B cell depletion by rituximab may also attenuate the activity of SS. This case report is the first to describe the effect of rituximab on histological and sialometric/chemical characteristics of SS. The efficacy of rituximab in the treatment of SS warrants further investigation.
- RF, rheumatoid factor
- SS, Sjögren’s syndrome
- MALT lymphoma
- Sjögren’s syndrome
Statistics from Altmetric.com
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Sjögren’s syndrome (SS) is a chronic inflammatory and lymphoproliferative disease with autoimmune features. The main clinical features are progressive dryness of the mouth (xerostomia) and dryness of the eyes (keratoconjunctivitis sicca), but various systemic complications can also occur. SS is associated with high B cell activity as reflected by hypergammaglobulinaemia and the presence of several autoantibodies such as rheumatoid factor (RF), antinuclear antibodies, and anti-Ro/SSA and anti-La/SSB antibodies. Moreover, 5% of patients develop malignant B cell lymphoma, usually located in the major salivary glands.1 Most of these lymphomas are of mucosa associated lymphoid tissue (MALT) type, and usually have an indolent course, with a 5 year overall survival of 90%.2
The optimal management of MALT lymphoma in patients with SS has not been clearly defined. Surgery, chemotherapy, and radiotherapy, alone or in combination, have been used. Conventional radiotherapy achieves excellent control in localised MALT lymphoma, but may cause a significant decrease of salivary gland function.3 Rituximab, a monoclonal antibody directed towards CD20 on B cells, is a promising new drug not only for the treatment of B cell lymphomas4,5 but also for various autoimmune disorders.6 Such an approach may be especially promising in the treatment of SS associated MALT lymphoma, because radiation injury to salivary gland tissue, a well known cause of progressive xerostomia, can be avoided. Furthermore, because B cells appear to be involved in the pathogenesis of SS, SS disease activity may also be attenuated and, ultimately, this may even result in amelioration of xerostomia. We present a patient with SS complicated by MALT lymphoma localised on the hard palate and in the parotid gland. The MALT lymphoma completely disappeared and a beneficial effect on histological, serological, and functional parameters of SS was seen after treatment with rituximab.
A 42 year old woman was referred to our clinic in August 2002 because of a large swelling on the hard palate with a diameter of 2 cm. Ten years earlier, two enlarged lymph nodes in the neck had been excised elsewhere and at that time classified as benign lymphoepithelial lesions. She used no drugs. An incision biopsy from the palatal swelling and a review of the excised lymph nodes from 10 years before showed MALT lymphoma. Some small cervical and axillary lymph nodes, 5 mm in size, were visible on a computed tomography scan. Screening for SS showed decreased salivary gland function (unstimulated whole saliva flow of 0.06 ml/min; stimulated whole saliva flow of 0.27 ml/min) and globular sialectasia on parotid sialography. Schirmer’s test was 0/0 mm/min ODS and the rose bengal score was 7/7 ODS. Positive tests for autoantibodies (anti-SSA and anti-SSB), IgM RF at a level of 107 kU/l, and an increased level of total IgG of 25.1 g/l were found. An incision biopsy of the right parotid gland (according to Kraaijenhagen7) performed to confirm the diagnosis of SS, showed lymphoepithelial lesions consistent with SS, and a coexistent MALT lymphoma. The patient fulfilled the criteria for primary SS, complicated by MALT lymphoma localised on the hard palate, the parotid gland, and, most probably, in the lymph nodes as based on review histology.
She was treated weekly with a course of four infusions of rituximab (375 mg/m2), without high dose corticosteroids or other immunosuppressive drugs. No serious adverse effects were seen. The effect of rituximab treatment on MALT lymphoma as evaluated by complete clinical restaging and on SS activity as demonstrated by serological, sialometric/chemical, and lachrymal measures, was assessed 3 months (MALT, SS) and 6 months (SS) after treatment. In addition, a second incision biopsy of the right parotid gland was taken 3 months after treatment.
Complete clinical remission of the MALT lymphoma was achieved. Serological analysis showed a slight decrease of the IgG level without modification of the autoantibody status. Objective tests disclosed mild improvement of the stimulated salivary secretion and of the concentration of sodium in saliva. Also some improvement was observed in lachrymal function, although it remained at a pathological level (Schirmer’s test, <5 mm at 5 min) (table 1). The subjective complaints showed some improvement as assessed by patient scored visual analogue scores for sicca complaints and a overall decrease of fatigue according to the Multidimensional Fatigue Inventory.8 The parotid gland biopsy after treatment showed no signs of MALT lymphoma by morphological and molecular analysis. Also, a regression was noted in the histopathological characteristics of SS. There was a decrease of the lymphoid infiltrate, now mainly consisting of T cells, with recovery of salivary gland tissue morphology. Immunohistological analysis of the infiltrate in the second biopsy specimen showed an increase in the relative percentage of IgA positive plasma cells as compared with IgG positive plasma cells (table 1, fig 1).
Anti-B cell monoclonal antibody treatment is a promising new treatment for autoimmune disorders. Initial data have shown that rituximab is efficacious and relatively safe in systemic diseases such as rheumatoid arthritis, Wegener’s granulomatosis, and systemic lupus erythematosus.6,10 Although SS is considered to be a T cell mediated disease, its systemic complications are associated with increased B cell activity. A positive effect of rituximab on clinical measures of both SS and MALT lymphoma in patients with SS has been reported in case reports,11,12 and in a study of four patients with aggressive lymphoma and SS treated with rituximab combined with chemotherapy (R-CHOP).13 However, none of these reports examined histological variables, gland-specific salivary flow, and salivary composition.
In our patient, increased salivary output (stimulated whole saliva) was seen, mainly because of an increased stimulated secretion of the submandibular/sublingual glands. Analysis of the parotid saliva showed a decrease in sodium concentration, indicating normalisation of the sodium readsorption by the salivary gland ductal system, as in healthy subjects most of the sodium is reabsorbed from primary saliva during its transport through the ductal system. This finding is in agreement with a reduction of the inflammatory component of the secretory salivary gland cells in autoimmune sialoadenitis.9 Lachrymal gland function improved only at 6 months after treatment.
The pretreatment biopsy specimen showed less salivary gland tissue than the specimen obtained after rituximab treatment. Whether B cell depletion led to recovery or regeneration of salivary gland tissue, which is possible in this timeframe,14 or whether this observation was due to sampling error, remains uncertain. No increase in parotid gland function was seen, but longer follow up is necessary. The inflammatory infiltrate was reduced with a change in plasma cells which produce immunoglobulin. The presence of IgA positive plasma cells at <70% or of IgM positive plasma cells at ⩾10%, as studied in labial salivary gland biopsy specimens, is highly specific for SS. The percentage of IgA positive plasma cells and the percentage of IgM positive plasma cells in the post-treatment biopsy specimen was still compatible with SS (58% and 16%, respectively), but there was a clear increase of the percentage of IgA positive plasma cells and a decrease of the percentage of IgM positive cells compared with the biopsy performed before treatment (26% and 24%, respectively). The decrease of IgA positive plasma cells at baseline might be the consequence of massive infiltration of lymphomatous B cells, which most commonly express surface IgM, often in combination with cytoplasmic IgM in the neoplastic plasma cells. As a result, the increase of the percentage of IgA positive plasma cells after treatment might be just a mechanical consequence of the disappearance of lymphomatous B cells. However, this assumption, at best, explains only part of the phenomena observed, as in contrast with the increase of IgA plasma cells, there was a marked concomitant decrease of IgG positive plasma cells. This change in the IgA/IgG plasma cell ratio suggests a treatment related decrease of SS activity.15 Further support for the decrease in disease activity comes from the reduced concentration of sodium in parotid saliva, which also reflects a decrease of inflammation at tissue level. Furthermore, the plasma cells in the second biopsy specimen were polyclonal, which was confirmed by polymerase chain reaction. After 6 months, IgM RF returned to the baseline value, whereas sialometric and chemical values remained stable.
As far as we know, this case report is the first to describe the effects of rituximab without other immunosuppressive drugs on histological and functional parameters in a patient with SS associated MALT lymphoma. The histological, serological, and functional components of SS in our patient improved after treatment with rituximab. IgM RF is produced by short lived plasma cells and might be a good surrogate marker for SS activity—for example, an increase of IgM RF might indicate the need for re-treatment. In addition, repeated parotid gland biopsies may offer an objective tool for evaluating treatment in patients with SS with or without associated lymphoma. A parotid gland biopsy has several advantages compared with a labial biopsy. There is more tissue available, follow up biopsies from the same gland are possible, and morbidity of an incision biopsy of the parotid gland is comparable16 or, in our hands, even less than that of a labial biopsy (unpublished data). Rituximab might be of therapeutic value in the preservation of function of the exocrine glands in patients with active SS, especially in patients with residual salivary gland function. A phase II study in patients with SS is currently underway.